Details

Autor(en) / Beteiligte

• Ben Khaled, Najib
• Seidensticker, Max
• Ricke, Jens
• Mayerle, Julia
• Oehrle, Bettina
• Rössler, Daniel
• Teupser, Daniel
• Ehmer, Ursula
• Bitzer, Michael
• Waldschmidt, Dirk
• Fuchs, Martin
• Reuken, Philipp A
• Lange, Christian M
• Wege, Henning
• Kandulski, Arne
• Dechêne, Alexander
• Venerito, Marino
• Berres, Marie-Luise
• Luedde, Tom
• Kubisch, Ilja
• Reiter, Florian P
• De Toni, Enrico N

Titel

Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol

Ist Teil von

• Future oncology (London, England), 2022-04, Vol.18 (12), p.1423-1435

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab is the first approved immunotherapeutic regimen for first-line therapy in patients with unresectable hepatocellular carcinoma (HCC), currently approved in more than 80 countries. The efficacy and tolerability of this regimen suggest that the use of atezolizumab + bevacizumab could be extended to the treatment of patients with intermediate-stage HCC in combination with transarterial chemoembolization (TACE). The authors describe the rationale and design of the DEMAND study. This investigator-initiated, multicenter, randomized phase II study is the first trial to evaluate the safety and efficacy of atezolizumab + bevacizumab prior to or in combination with TACE in patients with intermediate-stage HCC. The primary end point is the 24-month survival rate; secondary end points include objective response rate, progression-free survival, safety and quality of life. Clinical Trial Registration:  (ClinicalTrials.gov).